STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment

Cancer Research

Volumn 76, Issue 5, 2016, Pages 999-1008

  Koyama, Shohei ^a,b   Akbay, Esra A ^a,b   Li, Yvonne Y ^a,b   Aref, Amir R ^a,b   Skoulidis, Ferdinandos ^c   Herter Sprie, Grit S ^a,b   Buczkowski, Kevin A ^a   Liu, Yan ^a,b   Awad, Mark M ^a,b   Denning, Warren L ^c   Diao, Lixia ^c   Wang, Jing ^c   Parra Cuentas, Edwin R ^c   Wistuba, Ignacio I ^c   Soucheray, Margaret ^d   Thai, Tran ^a   Asahina, Hajime ^a,b   Kitajima, Shunsuke ^a   Altabef, Abigail ^a   Cavanaugh, Jillian D ^a   Rhee, Kevin ^a   Gao, Peng ^a   Zhang, Haikuo ^a,b   Fecci, Peter E ^e   Shimamura, Takeshi ^f   Hellmann, Matthew D ^g   Heymach, John V ^c   Hodi, F Stephen ^a,b   Freeman, Gordon J ^a,b   Barbie, David A ^a,b   Dranoff, Glenn ^h   Hammerman, Peter S ^a,b,h   Wong, Kwok Kin ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE LKB1; RNA; CD274 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN; STK11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER TISSUE; CELL ACTIVITY; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME DEFICIENCY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LUNG LAVAGE; MOUSE; NEUTROPHIL; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RNA SEQUENCE; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DEFICIENCY; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MUTATION; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, CD274; CYTOKINES; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MUTATION; NEUTROPHIL INFILTRATION; PROTEIN-SERINE-THREONINE KINASES; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84961858396     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1439     Document Type: Article

References (37)

1. Cardarella S, Johnson BE. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 2013;188:770-5.
2. The Cancer Genome Atlas Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
3. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-10.
4. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012;483:613-7.
5. Zhao N, Wilkerson MD, Shah U, Yin X, Wang A, Hayward MC, et al. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 2014;86:255-61.
6. Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, et al. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS mutant lung adenocarcinoma. Clin Cancer Res 2015;21:2851-60.
7. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
8. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
9. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
10. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
11. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, et al. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res 2011;4:51-64.
12. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007;21:1714-9.
13. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
14. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462:104-7.
15. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013;39:61-73.
16. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 2013;3:870-9.
17. Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 2013;19:6183-92.
18. Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014;4:452-65.
19. Tchaicha JH, Akbay EA, Altabef A, Mikse OR, Kikuchi E, Rhee K, et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res 2014;74:4676-84.
20. Franciszkiewicz K, Boutet M, Gauthier L, Vergnon I, Peeters K, Duc O, et al. Synaptic release of CCL5 storage vesicles triggers CXCR4 surface expression promoting CTL migration in response to CXCL12. J Immunol 2014;193:4952-61.
21. Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002;169:424-33.
22. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013;3:49.
23. Walker F, Zhang HH, Matthews V, Weinstock J, Nice EC, Ernst M, et al. IL6/sIL6R complex contributes to emergency granulopoietic responses in G-CSF- and GM-CSF-deficient mice. Blood 2008;111:3978-85.
24. Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014;13:496-502.
25. Leslie K, Gao SP, Berishaj M, Podsypanina K, Ho H, Ivashkiv L, et al. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res 2010;12:R80.
26. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, etal. Endothelial expressionofPD-L1 and PD-L2 down-regulates CD8+Tcell activation and cytolysis. Eur J Immunol 2003;33:3117-26.
27. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
28. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
29. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572-6.
30. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
31. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 2015;5:860-77.
32. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010;10:826-37.
33. Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, et al. Unique versus redundant functions of IL-1alpha and IL-1beta in the tumor microenvironment. Front Immunol 2013;4:177.
34. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008;222:287-98.
35. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest 2014;124:5466-80.
36. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
37. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.